LIPID-RELEASING LEUKOCYTE ABILITY IS A RISK FACTOR FOR DEVELOPING ATHEROSCLEROSIS AND ATHEROSCLEROTIC PROCESS ACTIVITY MARKER IN PATIENTS WITH OBLITERATING ARTERIAL LOWER EXTREMITIES ATHEROSCLEROSIS AND DIABETIC FOOT SYNDROME
- Authors: Kharuzina OV1, Sandakov PY.1, Mishlanov VY.1, Seredenko NN1, Vladimirsky VE1
-
Affiliations:
- Issue: Vol 30, No 4 (2013)
- Pages: 49-55
- Section: Articles
- Submitted: 12.07.2016
- Published: 15.08.2013
- URL: https://permmedjournal.ru/PMJ/article/view/3328
- DOI: https://doi.org/10.17816/pmj30449-55
- ID: 3328
Cite item
Full Text
Abstract
Aim. To determine the pathogenetic significance of nonspecific inflammation factors in atherogenesis and lipid-releasing leukocyte ability (LRLA) in patients with obliterating arterial lower extremities atherosclerosis in combined course of atherosclerosis of different vascular pools (coronary, branchiocephalic arteries) and diabetic foot syndrome. Materials and methods. The study included 83 patients: 72 patients with obliterating atherosclerosis of lower extremities vessels, 11 – with diabetic foot syndrome. The control group consisted of 20 practically healthy persons. All patients were investigated with instrumental and laboratory methods. Lipid-releasing leukocyte ability was assessed using Professor A.V. Tuev, Professor V.Yu. Mishlanov method. Patients underwent operative treatment including prosthetics, shunting, endarterectomy, thrombectomy, sympathectomy, stenting, balloon dilatation depending on the course of disease, level of arterial bed lesion, degree of extremities ischemia and associated pathology. Results. Comparative analysis of the results of laboratory LRLA values was carried out in patients with isolated associated lesion of lower extremities arteries and diabetic foot syndrome. In the groups of patients with isolated and associated atherosclerosis there are reliable differences. After operative treatment, LRLA is decreased that causes reduction of atherogenesis risk. No differences were detected in case of association with diabetic foot syndrome. Ambulatory treatment in the postoperative period included angioprotectors, disaggregants, statins (simvastatin – 20–40 mg or atorvastatin – 10 mg, constantly). Conclusion. LRLA is a risk factor for developing obliterating atherosclerosis of lower extremities and associated lesion of arterial bed. Maximum LRLA values were revealed in the group of patients with diabetic foot syndrome and associated lesion of different arterial pools. Effective operative treatment of patients with OLEA is accompanied by significant decrease in LRLA value. No LRLA dynamics in the postoperative period among patients with DF syndrome was de
Full Text
Липидвысвобождающая способность лейкоцитов – фактор риска развития атеросклероза и маркер активности атеросклеротического процесса у больных с облитерирующим атеросклерозом артерий нижних конечностей и синдромом диабетической стопы×
About the authors
O V Kharuzina
Email: olga.haruzina@mail.ru
P Ya Sandakov
V Yu Mishlanov
N N Seredenko
V E Vladimirsky
References
- Бокерия Л. А., Гудкова Р. Г. Сердечно-сосу-дистая хирургия 2000. М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН 2001; 68.
- Гавриленко А. В., Омаржанов О. А., Абрамян А. В. Микроциркуляция у больных с хронической ишемией нижних конечностей. Ангиология и сосудистая хирургия 2003; 9 (2): 130–135.
- Гавриленко А. В., Кохан Е. П., Абрамян А. В. Применение поясничной симпатэктомии в лечении облитерирующих заболеваний артерий нижних конечностей – современный взгляд на проблему. Ангиология и сосудистая хирургия 2004; 3: 80.
- Затевахин И. И., Юдин Р. Ю., Комраков В. Е. Облитерирующий тромбангиит. М. 2002; 320.
- Покровский А. В., Дан В. Н., Чупин А. В., Харазов А. Ф. Возможности сохранения нижней конечности при критической ишемии у больных сахарным диабетом. Сахарный диабет 2002; 4: 28–32.
- Туев А. В., Мишланов В. Ю. Экспериментальные предпосылки новой теории атерогенеза. Болезни сердечно-сосудистой системы: теория и практика: материалы I съезда кардиологов Приволжского и Уральского федеральных округов РФ. Пермь 2003; 258–265.
- Jackson M. R., Clagett G. P. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001; 119: 283–299.